ImmunoCellular Therapeutics, Ltd.(NYSEMKT:IMUC) Continues Its Cancer Immunity Program

793

Dallas, Texas 01/16/2014 (FINANCIALSTRENDS) – ImmunoCellular Therapeutics, Ltd.(NYSEMKT:IMUC)  has been in the business of developing therapies, using its core biotechnology based techniques which promote immunology solutions. The company has, in the past year testing one of its lead candidates for the treatment of a rare type of brain tumor called the Glioblastoma multiforme or GBM. Though the vaccine – ICT-107- which is delivered through dendritic cells. Currently, patients who have been diagnosed with this condition, and have completed resection as well as chemoradiation options are under consideration.

Statistical significance

ImmunoCellular Therapeutics, Ltd.(NYSEMKT:IMUC) had noted that there was in increase in progression-free survival given the quality of statistical significance. It was found that GBM carrying patients showed difference time lines of survival for ICT as well as placebo controlled study. It was found that when placebo was used, ICT-107 was found to have two months additional time line.
GMB is considered to be one of the fast spreading cancer conditions. Unfortunately this rare form of cancer is known to cause death in less than 3 to 4 months of first detection. The tumor which progresses to malignancy very rapidly boasts of higher median survival time with the use of some therapies as currently available in the market- Temozolomide, which is product marketed by Merck and company. This drug, though known to have been introduced back in 2005, is the last know drugs used in treating GMB. The drug is known to improve the median survival point for patients who have just been diagnosed as GBM, from the accepted 12.1 months to over 14.6 months.

The vaccine therapy provider for GBM and other turmors has 494,106 volume and $54.81 billion market cap. The US company has a 52 week high of $4.00 and 52 week low of $0.65. EPS is0 0.05.The stock prices were found to rally as ICT-121, Immunocellular Therapeutics second vaccine showed that the Phase I study had administered it to the first patient.

Subscribe to get your free report!

* indicates required
*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.